Pieris Pharmaceuticals Stock Forecast, Price & News

Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

Is Pieris Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pieris Pharmaceuticals stock.
View analyst ratings for Pieris Pharmaceuticals or view top-rated stocks.

How has Pieris Pharmaceuticals' stock price been impacted by Coronavirus?

Pieris Pharmaceuticals' stock was trading at $2.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PIRS stock has increased by 46.2% and is now trading at $3.26.
View which stocks have been most impacted by COVID-19.

Are investors shorting Pieris Pharmaceuticals?

Pieris Pharmaceuticals saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 694,000 shares, a decline of 75.4% from the October 31st total of 2,820,000 shares. Based on an average daily trading volume, of 1,250,000 shares, the short-interest ratio is presently 0.6 days. Currently, 1.2% of the company's shares are short sold.
View Pieris Pharmaceuticals' Short Interest.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Pieris Pharmaceuticals.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.24). Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 120.25% and a negative net margin of 205.44%. During the same period in the previous year, the firm earned ($0.26) EPS.
View Pieris Pharmaceuticals' earnings history.

What price target have analysts set for PIRS?

3 Wall Street analysts have issued twelve-month target prices for Pieris Pharmaceuticals' stock. Their forecasts range from $8.00 to $9.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $8.50 in the next twelve months. This suggests a possible upside of 160.7% from the stock's current price.
View analysts' price targets for Pieris Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the following people:

• Stephen S. Yoder, President, Chief Executive Officer & Director
• Thomas Bures, Senior VP, Chief Financial & Accounting Officer
• Hitto Kaufmann, Chief Scientific Officer & Senior Vice President
• Tim Demuth, Chief Medical Officer & Senior Vice President
• Ahmed S. Mousa, Secretary, Chief Business Officer & Senior VP

Who are some of Pieris Pharmaceuticals' key competitors?

Some companies that are related to Pieris Pharmaceuticals include Design Therapeutics (DSGN), Seres Therapeutics (MCRB), Heron Therapeutics (HRTX), Arcturus Therapeutics (ARCT), Edgewise Therapeutics (EWTX), Vanda Pharmaceuticals (VNDA), RAPT Therapeutics (RAPT), Zealand Pharma A/S (ZEAL), Tango Therapeutics (TNGX), Phibro Animal Health (PAHC), Zymeworks (ZYME), Repare Therapeutics (RPTX), AnaptysBio (ANAB), Kiniksa Pharmaceuticals (KNSA) and Praxis Precision Medicines (PRAX).
View all of PIRS's competitors.

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL).

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.84%), Morgan Stanley (2.41%), Invesco Ltd. (2.08%), BlackRock Inc. (1.77%), Two Sigma Investments LP (1.62%) and Two Sigma Advisers LP (1.55%). Company insiders that own Pieris Pharmaceuticals stock include Aquilo Capital Management, Llc and Shane Olwill.
View institutional ownership trends for Pieris Pharmaceuticals.

Which institutional investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Platinum Investment Management Ltd., Squarepoint Ops LLC, Jane Street Group LLC, BlackRock Inc., HAP Trading LLC, and Credit Suisse AG.
View insider buying and selling activity for Pieris Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Pieris Pharmaceuticals stock?

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Two Sigma Investments LP, Two Sigma Advisers LP, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, Cutter & CO Brokerage Inc., Connor Clark & Lunn Investment Management Ltd., and Marshall Wace LLP.
View insider buying and selling activity for Pieris Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $3.26.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals has a market capitalization of $234.92 million and generates $29.32 million in revenue each year. The biotechnology company earns $-37.23 million in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

Pieris Pharmaceuticals employs 117 workers across the globe.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is www.pieris.com.

Where are Pieris Pharmaceuticals' headquarters?

Pieris Pharmaceuticals is headquartered at 255 State Street 9th Floor, Boston MA, 02109.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at (857) 246-8998, via email at [email protected], or via fax at 49-8161-141-1444.